Gebbia V, Maiello E, Giuliani F, Borsellino N, Caruso M, Di Maggio G, Ferraù F, Bordonaro R, Verderame F, Tralongo P, Di Cristina L, Agueli R, Russo P, Colucci G
Department of Experimental Oncology and Clinical Applications, University of Palermo, La Maddalena Clinic for Cancer, Palermo, Italy.
Ann Oncol. 2007 Jun;18 Suppl 6:vi124-7. doi: 10.1093/annonc/mdm240.
In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support.
A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity.
Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1-7 months), and median overall survival (OS) was 6.7 months (range 2-9 months). A stabilization of performance status (PS) and a subjective improvement of cancer-related symptoms were recorded in 27 patients.
Data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of adenocarcinoma of the pancreas patients. The use of SLCT, however, should be carefully proposed to patients with good PS or those who had a good response to first-line therapy.
在日常临床实践中，对于吉西他滨一线化疗失败的晚期胰腺癌患者，常给予二线化疗（SLCT），但缺乏可靠的科学依据。
进行了一项回顾性调查，纳入42例患者。患者每两周接受标准的FOLFOX4方案治疗，直至病情进展或出现不可接受的毒性反应。
记录到6例部分缓解（14%）和16例病情稳定（38%），肿瘤生长控制率为57%。中位疾病进展时间（TtP）为4个月（范围1 - 7个月），中位总生存期（OS）为6.7个月（范围2 - 9个月）。27例患者的体能状态（PS）稳定，癌症相关症状有主观改善。
本文所呈现的数据支持FOLFOX4方案用于胰腺癌患者的二线治疗。然而，对于PS良好或对一线治疗反应良好的患者，应谨慎考虑给予SLCT。
Zotero 插件